Diakonos Oncology

Diakonos Oncology, headquartered in Houston, Texas, is a clinical-stage biotechnology company committed to revolutionizing cancer immunotherapy and focusing on difficult-to-treat indications, including glioblastoma. Variants of the DOC1021 therapeutic platform are also in early clinical trials for pancreatic ductal adenocarcinoma (PDAC) and cutaneous angiosarcoma (AS).